PT3424932T - Boronoftalidas para utilização terapêutica - Google Patents

Boronoftalidas para utilização terapêutica

Info

Publication number
PT3424932T
PT3424932T PT181873902T PT18187390T PT3424932T PT 3424932 T PT3424932 T PT 3424932T PT 181873902 T PT181873902 T PT 181873902T PT 18187390 T PT18187390 T PT 18187390T PT 3424932 T PT3424932 T PT 3424932T
Authority
PT
Portugal
Prior art keywords
boronophthalides
therapeutic use
therapeutic
Prior art date
Application number
PT181873902T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3424932(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of PT3424932T publication Critical patent/PT3424932T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT181873902T 2005-02-16 2006-02-16 Boronoftalidas para utilização terapêutica PT3424932T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65406005P 2005-02-16 2005-02-16

Publications (1)

Publication Number Publication Date
PT3424932T true PT3424932T (pt) 2021-05-19

Family

ID=36917059

Family Applications (4)

Application Number Title Priority Date Filing Date
PT15171026T PT2987796T (pt) 2005-02-16 2006-02-16 Boronoftalidas substituídas por halogéneo para o tratamento de infecções
PT67352823T PT1853251E (pt) 2005-02-16 2006-02-16 Boroftalidas substituídas com halogéneo para o tratamento de infecções
PT181873902T PT3424932T (pt) 2005-02-16 2006-02-16 Boronoftalidas para utilização terapêutica
PT111545752T PT2343304E (pt) 2005-02-16 2006-02-16 Compostos de boronoftalidas biocidas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT15171026T PT2987796T (pt) 2005-02-16 2006-02-16 Boronoftalidas substituídas por halogéneo para o tratamento de infecções
PT67352823T PT1853251E (pt) 2005-02-16 2006-02-16 Boroftalidas substituídas com halogéneo para o tratamento de infecções

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT111545752T PT2343304E (pt) 2005-02-16 2006-02-16 Compostos de boronoftalidas biocidas

Country Status (25)

Country Link
US (11) US7582621B2 (en:Method)
EP (4) EP3424932B1 (en:Method)
JP (6) JP5038912B2 (en:Method)
KR (4) KR101337045B1 (en:Method)
CN (2) CN101914109B (en:Method)
AU (3) AU2006214247C1 (en:Method)
BR (1) BRPI0608431B8 (en:Method)
CA (1) CA2597982C (en:Method)
CY (3) CY1120695T1 (en:Method)
DK (3) DK3424932T3 (en:Method)
ES (4) ES2414095T3 (en:Method)
FR (1) FR20C1024I2 (en:Method)
HU (4) HUE026021T2 (en:Method)
IL (2) IL207156A (en:Method)
LT (1) LTC2343304I2 (en:Method)
LU (1) LUC00157I2 (en:Method)
MX (1) MX369262B (en:Method)
NL (1) NL301049I2 (en:Method)
NZ (3) NZ560448A (en:Method)
PL (4) PL2343304T3 (en:Method)
PT (4) PT2987796T (en:Method)
RU (3) RU2414906C2 (en:Method)
SI (3) SI2343304T1 (en:Method)
WO (1) WO2006089067A2 (en:Method)
ZA (4) ZA200707408B (en:Method)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
KR101337045B1 (ko) * 2005-02-16 2013-12-05 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
US7793666B2 (en) * 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
AU2006333527B2 (en) * 2005-12-30 2013-08-01 Anacor Pharmaceuticals, Llc Boron-containing small molecules
PL2719388T3 (pl) * 2006-02-16 2019-11-29 Anacor Pharmaceuticals Inc Małe cząsteczki zawierające bor jako środki przeciwzapalne
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
EP1900378A1 (en) * 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
EP2187893A4 (en) * 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
US20100256092A1 (en) * 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US20100021530A1 (en) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enhanced trans-keratin drug delivery
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010045503A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010080558A1 (en) * 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
JP2012523424A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
AU2010281439A1 (en) * 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
US9440994B2 (en) * 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
WO2011019616A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011019612A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011022337A1 (en) 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011063293A1 (en) 2009-11-20 2011-05-26 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antihelminth agents
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
RU2432158C1 (ru) * 2010-07-28 2011-10-27 Закрытое акционерное общество "Институт прикладной нанотехнологии" Профилактический бактерицидный лак для обработки ногтей
ES2691468T3 (es) 2010-08-10 2018-11-27 Rempex Pharmaceuticals, Inc. Derivados de éster del ácido borónico cíclicos y usos terapéuticos de los mismos
PL3251678T3 (pl) 2010-09-07 2022-01-10 Anacor Pharmaceuticals, Inc. Pochodne benzoksaborolu do leczenia zakażeń bakteryjnych
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9162999B2 (en) 2011-09-28 2015-10-20 Wisconsin Alumni Research Foundation Catalytic conversion of cellulose to fuels and chemicals using boronic acids
RU2604496C2 (ru) * 2011-10-07 2016-12-10 Зингента Партисипейшнс Аг Способ защиты полезных растений или растительного материала для размножения
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
SG11201505855UA (en) 2013-01-30 2015-08-28 Dow Agrosciences Llc Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US8669207B1 (en) * 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9598443B2 (en) 2013-02-01 2017-03-21 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
AR094961A1 (es) 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
CN104224810B (zh) * 2013-06-20 2017-04-19 中国科学院上海生命科学研究院 一种化合物及其衍生物治疗肺炎球菌感染性疾病的用途
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
SI3030519T1 (sl) 2013-08-09 2022-04-29 Glaxosmithkline Intellectual Property (No.2) Limited Triciklične benzoksaborolne spojine in njihove uporabe
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
CA3052643A1 (en) 2013-11-22 2015-05-28 Bausch Health Ireland Limited Anti-infective methods, compositions, and devices
UY36000A (es) * 2014-02-17 2015-09-30 Syngenta Participations Ag ?compuestos microbicidas, método para controlar o prevenir la infestación de microorganismos fitopa togenos, y composición de los mismos?.
WO2015134500A1 (en) 2014-03-03 2015-09-11 Cook Medical Technologies Llc Mechanical dilator
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
JP2015212249A (ja) * 2014-05-05 2015-11-26 アナコール ファーマシューティカルズ，インコーポレイテッド 化合物および爪光沢剤
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
SG11201609020VA (en) * 2014-05-12 2016-11-29 Agrofresh Inc Volatile applications against pathogens
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
EP3164406B1 (en) 2014-07-01 2024-12-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016001834A1 (en) 2014-07-01 2016-01-07 Daiichi Sankyo Company, Limited Tricyclic benzoxaboroles as antibacterial agents
CN113368215A (zh) 2014-10-21 2021-09-10 赫希玛有限公司 一种治疗方法
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR101580077B1 (ko) * 2015-03-28 2015-12-24 한국콜마주식회사 시크로피록스 함유 네일락카 조성물
WO2016164589A1 (en) 2015-04-09 2016-10-13 The Penn State Research Foundation Synergistic benzoxaborole-containing anti-fungicidal composition
AU2016246802A1 (en) 2015-04-09 2017-10-05 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US11174267B2 (en) 2015-06-12 2021-11-16 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
CA3014757C (en) * 2015-08-06 2020-01-14 The Penn State Research Foundation Benzoxaborole-containing coating resistant to cellulose-supportable fungus
CN106467557B (zh) * 2015-08-18 2019-05-03 北京海美桐医药科技有限公司 他瓦硼罗的一种制备方法
IL259693B2 (en) 2015-11-30 2025-01-01 Anacor Pharmaceuticals Llc Topical preparations and their use in the treatment of inflammation
EP3423159A4 (en) * 2016-03-02 2019-11-06 Anacor Pharmaceuticals, Inc. BORN SMALL MOLECULES
US10611780B2 (en) 2016-03-02 2020-04-07 Bill And Melinda Gates Foundation Boron-containing small molecules
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
TW201735792A (zh) 2016-03-07 2017-10-16 農業保鮮股份有限公司 使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法
WO2017155877A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Vaporized administration of pesticides
US11773113B2 (en) * 2016-05-09 2023-10-03 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CA3026582A1 (en) 2016-06-30 2018-01-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US20170305936A1 (en) 2016-07-12 2017-10-26 Pliva Hrvatska D.O.O. Solid state forms of crisaborole
US10743232B1 (en) 2016-11-15 2020-08-11 Sprint Spectrum L.P. Controlling handover based on carrier-aggregation policies and UE capabilities
WO2018115362A1 (en) 2016-12-22 2018-06-28 Laboratorios Lesvi, Sl Process for preparing 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
WO2018150327A1 (en) * 2017-02-14 2018-08-23 Wavelength Enterprises Ltd Crisaborole production process
EP3576747A4 (en) * 2017-03-09 2020-12-16 The Penn State Research Foundation SMALL MOLECULES CONTAINING BORON TO INHIBIT THE ACTIVITY OF A RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE
WO2018207216A1 (en) 2017-05-12 2018-11-15 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (crisaborole)
US10865217B2 (en) 2017-05-23 2020-12-15 Msn Laboratories Private Limited, R & D Center Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
IL273551B2 (en) 2017-10-11 2024-02-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis
CA3080891A1 (en) 2017-11-02 2019-05-09 Halcyon Labs Private Limited Novel process for the preparation tavaborole and its intermediates
EP3716766A4 (en) 2017-11-30 2021-12-22 Boragen, Inc. BENZOXABOROLE COMPOUNDS AND THEIR FORMULATIONS
US10329311B1 (en) 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
CN108148085B (zh) * 2018-01-04 2019-11-01 合肥医工医药股份有限公司 具有抑制磷酸二酯酶4的化合物、制法及其药物用途
CA3087139A1 (en) 2018-01-09 2019-07-18 Halcyon Labs Private Limited Process for the preparation of crisaborole and its intermediates
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN108451898A (zh) * 2018-04-03 2018-08-28 苏州尚宜佳生物科技有限公司 一种克立硼罗温敏凝胶剂及其制备方法和应用
CA3097127A1 (en) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
CN108659024A (zh) * 2018-07-24 2018-10-16 武汉轻工大学 克立硼罗的制备方法
US20210275554A1 (en) * 2018-07-31 2021-09-09 MC2 Therapeutics Limited Topical compsition
CA3148168A1 (en) 2018-08-18 2020-02-27 Chun Yu Liu Solid forms of substituted benzoxaborole and compositions thereof
DK3861001T3 (da) 2018-10-05 2024-01-15 Pfizer Bor, som indeholder PDE4-hæmmere
US20220160649A1 (en) 2019-03-20 2022-05-26 Rita DOBMEYER Pharmaceutical composition
WO2021015841A1 (en) * 2019-07-25 2021-01-28 Massachusetts Institute Of Technology Boron-containing pharmacophore
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
US20230340530A1 (en) 2020-08-31 2023-10-26 Pfizer Inc. Methods of Protecting RNA
CN114644645B (zh) * 2022-03-08 2023-05-26 南京农业大学 3-吲哚取代苯硼唑类化合物及其制备方法和应用
CA3239096A1 (en) 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US5688258A (en) 1995-05-02 1997-11-18 The Procter & Gamble Company Disposable cover for an absorbent materials
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
WO1998024753A1 (en) 1996-12-02 1998-06-11 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP2223920A3 (en) 1996-06-19 2011-09-28 Aventis Pharma Limited Substituted azabicyclic compounds
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
AU4486097A (en) 1996-09-19 1998-04-14 Board Of Trustees Of The Leland Stanford Junior University Dna adenine methyltransferases and uses thereof
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
JP2003517447A (ja) 1998-11-06 2003-05-27 ビーエーエスエフ アクチェンゲゼルシャフト 三環式ピラゾール誘導体
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
EP1155698A4 (en) 1999-01-29 2003-01-15 Nitto Kasei Co Ltd ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY
CA2373279A1 (en) 1999-05-25 2000-12-14 The Penn State Research Foundation Dna methyltransferase inhibitors
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
CA2383554C (en) 1999-08-25 2008-03-18 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6369098B1 (en) 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
JP2003519188A (ja) * 2000-01-06 2003-06-17 マランテック ホールディング リミテッド ライアビリティ カンパニー 皮膚増殖の促進及び皮膚症状の処置のための組成物及び方法
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
EP1303625A2 (en) 2000-07-14 2003-04-23 Zycos Inc. Alpha-msh related compounds and methods of use
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
JP2004524281A (ja) 2000-11-30 2004-08-12 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチルトランスフェラーゼ阻害剤
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
ATE438615T1 (de) 2001-04-06 2009-08-15 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
US7217701B2 (en) 2001-10-11 2007-05-15 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
WO2003059916A2 (en) 2002-01-10 2003-07-24 The Pennsylvania State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
CA2491474A1 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
ES2283867T3 (es) 2002-12-02 2007-11-01 Solvias Ag Hidrogenacion catalitica de dobles enlaces de carbonoheteroatomo.
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
AU2003299821B2 (en) 2002-12-18 2010-02-18 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
WO2004081008A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
US20050125852A1 (en) 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
CN1829521B (zh) 2003-06-16 2011-01-26 安纳考尔医药公司 耐水解的含硼治疗剂和使用方法
JP2005022986A (ja) * 2003-06-30 2005-01-27 Sankyo Co Ltd Ｅｄｇ受容体拮抗作用を有するアルキン誘導体
DK1643998T3 (da) 2003-07-03 2007-12-27 Hoffmann La Roche NK1/NK3-antagonister til behandling af skizofreni
CN1922178A (zh) 2003-12-29 2007-02-28 3M创新有限公司 哌嗪、[1, 4 ]二氮杂环庚烷([1,4]diazepane ) 、[1, 4 ]二氮杂环辛烷([1, 4]diazocane)、和[1,5]二氮杂环辛烷([1,5] diazocane) 稠合的咪唑并环化合物
ES2464444T3 (es) 2004-05-12 2014-06-02 The Brigham And Women's Hospital, Inc. Gelsolina para uso en el tratamiento de infecciones
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
KR100624238B1 (ko) 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
WO2006062731A1 (en) 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
KR101337045B1 (ko) * 2005-02-16 2013-12-05 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
JP5084717B2 (ja) 2005-03-08 2012-11-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ キラル・ビスオキサゾリン触媒
AR054336A1 (es) 2005-03-30 2007-06-20 Astion Dev As Tratamiento de enfermedades dermatologicas y del prurito
US20080234229A1 (en) 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
AU2006333527B2 (en) * 2005-12-30 2013-08-01 Anacor Pharmaceuticals, Llc Boron-containing small molecules
PL2719388T3 (pl) 2006-02-16 2019-11-29 Anacor Pharmaceuticals Inc Małe cząsteczki zawierające bor jako środki przeciwzapalne
WO2007146965A2 (en) 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Compounds for the treatment of periodontal disease
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
EP2187893A4 (en) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
US20100256092A1 (en) 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
WO2010045503A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
AR088669A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro

Also Published As

Publication number Publication date
EP2987796A1 (en) 2016-02-24
KR20070112390A (ko) 2007-11-23
US20140142064A1 (en) 2014-05-22
AU2006214247A1 (en) 2006-08-24
US20060234981A1 (en) 2006-10-19
CA2597982C (en) 2014-07-08
LTPA2020524I1 (lt) 2020-09-10
AU2006214247C1 (en) 2012-11-08
EP1853251A2 (en) 2007-11-14
US20210070780A1 (en) 2021-03-11
JP2014132031A (ja) 2014-07-17
ES2414095T3 (es) 2013-07-18
FR20C1024I2 (fr) 2021-07-09
DK2987796T3 (en) 2018-09-17
RU2007134429A (ru) 2009-03-27
ES2872962T3 (es) 2021-11-03
DK2343304T3 (en) 2015-06-29
AU2010203096C1 (en) 2012-09-20
EP3424932A1 (en) 2019-01-09
US20160108063A1 (en) 2016-04-21
SI2987796T1 (sl) 2018-11-30
EP2343304B1 (en) 2015-06-10
PT2343304E (pt) 2015-08-26
NZ578297A (en) 2010-11-26
CY2020027I1 (el) 2021-01-27
NZ560448A (en) 2009-08-28
BRPI0608431B1 (pt) 2020-09-15
HK1160139A1 (en) 2012-08-10
HUE040060T2 (hu) 2019-02-28
CA2597982A1 (en) 2006-08-24
HK1221956A1 (en) 2017-06-16
DK3424932T3 (da) 2021-05-25
ZA200905950B (en) 2010-11-24
KR20100105869A (ko) 2010-09-30
JP5038912B2 (ja) 2012-10-03
MX369262B (es) 2019-11-04
SI3424932T1 (sl) 2021-08-31
LTC2343304I2 (lt) 2022-11-10
EP1853251A4 (en) 2010-01-13
PT1853251E (pt) 2013-07-19
PL2343304T3 (pl) 2015-09-30
HK1109735A1 (en) 2008-06-20
HUE026021T2 (en) 2016-05-30
IL185080A (en) 2012-07-31
US20190048026A1 (en) 2019-02-14
CN101914109B (zh) 2014-07-23
US8039451B2 (en) 2011-10-18
US20100190748A1 (en) 2010-07-29
LUC00157I2 (en:Method) 2021-07-06
PL1853251T3 (pl) 2013-09-30
JP2016020374A (ja) 2016-02-04
EP3424932B1 (en) 2021-04-07
RU2016145916A (ru) 2018-05-23
BRPI0608431A2 (pt) 2009-12-29
KR101456815B1 (ko) 2014-10-31
FR20C1024I1 (en:Method) 2020-07-31
AU2010203096A1 (en) 2010-08-12
ZA201506944B (en) 2018-08-29
ES2540966T3 (es) 2015-07-15
US8440642B2 (en) 2013-05-14
NZ598441A (en) 2013-07-26
HUS2000019I1 (hu) 2020-07-28
KR20130095330A (ko) 2013-08-27
RU2016145916A3 (en:Method) 2020-07-21
AU2006214247B2 (en) 2010-08-05
IL185080A0 (en) 2008-08-07
HUE054365T2 (hu) 2021-09-28
JP6046876B2 (ja) 2016-12-21
JP2010248265A (ja) 2010-11-04
CN101914109A (zh) 2010-12-15
JP2008535781A (ja) 2008-09-04
JP2013018778A (ja) 2013-01-31
US20170066788A1 (en) 2017-03-09
KR101426220B1 (ko) 2014-08-05
KR20130100019A (ko) 2013-09-06
EP1853251B1 (en) 2013-04-24
US20130244980A1 (en) 2013-09-19
ES2686981T3 (es) 2018-10-23
NL301049I1 (nl) 2020-07-01
CY2020027I2 (el) 2021-01-27
CY1124503T1 (el) 2022-07-22
CY1120695T1 (el) 2019-12-11
US20190330245A1 (en) 2019-10-31
PT2987796T (pt) 2018-10-18
KR101337068B1 (ko) 2013-12-06
NL301049I2 (nl) 2020-09-10
WO2006089067A3 (en) 2007-07-19
JP2017105826A (ja) 2017-06-15
AU2010203096B2 (en) 2010-12-02
BRPI0608431B8 (pt) 2021-05-25
EP2343304A1 (en) 2011-07-13
IL207156A (en) 2014-04-30
LUC00157I1 (en:Method) 2020-06-08
ZA200707408B (en) 2009-11-25
ZA201005380B (en) 2016-08-31
RU2010133524A (ru) 2012-02-20
PL3424932T3 (pl) 2021-09-20
CN101160124A (zh) 2008-04-09
PL2987796T3 (pl) 2018-12-31
KR101337045B1 (ko) 2013-12-05
US7582621B2 (en) 2009-09-01
RU2414906C2 (ru) 2011-03-27
WO2006089067A2 (en) 2006-08-24
RU2606947C2 (ru) 2017-01-10
US20150065459A1 (en) 2015-03-05
AU2011200994A1 (en) 2011-03-31
US8889656B2 (en) 2014-11-18
SI2343304T1 (sl) 2015-08-31
EP2987796B1 (en) 2018-08-08
US20110319361A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
PL3424932T3 (pl) Boronoftalidy do zastosowania terapeutycznego
GB0518390D0 (en) Therapeutic compounds
GB0518237D0 (en) Therapeutic compounds
GB0506147D0 (en) Therapeutic agents
GB0509326D0 (en) Therapeutic compounds
GB0509573D0 (en) Therapeutic compounds
GB0518361D0 (en) Therapeutic compounds
GB0519797D0 (en) Therapeutic agents
GB0522881D0 (en) Therapeutic compounds
GB0505437D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
GB0509405D0 (en) Therapeutic compounds
GB0518819D0 (en) Therapeutic agents
GB0519350D0 (en) Therapeutic agents
GB0518817D0 (en) Therapeutic agents
GB0513747D0 (en) Therapeutic compounds
GB0516661D0 (en) Therapeutic agents
GB0514738D0 (en) Therapeutic agents
GB0522130D0 (en) Therapeutic compounds
GB0507003D0 (en) Therapeutic
GB0526107D0 (en) Therapeutic Compounds
GB0518235D0 (en) Therapeutic compounds
GB0501655D0 (en) Therapeutic use
GB0518720D0 (en) Therapeutic combination
GB0515580D0 (en) Therapeutic compounds